Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meridian buys Gull at lower price:

This article was originally published in Clinica

Executive Summary

Meridian Diagnostics is to buy Fresenius subsidiary Gull Laboratories for $2.25 a share, down from $3 per share which was discussed when the deal was first announced in July. As a result of the deal, which is worth around $19 million, Gull will become a wholly-owned subsidiary of Cincinnati, Ohio-based Meridian. Meridian lowered its original offer earlier this month, basing its new offer on Gull's second-quarter results. Gull, of Salt Lake City, Utah, manufactures tests for the detection of infectious diseases and autoimmune disorders.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel